VFValentine Marie Ferré

Valentine Marie Ferré

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valentine Marie Ferré has a total of 193 co-authors. Here are the top co-authors by number of shared publications:

  • Charlotte Charpentier

    Service de Virologie, Université Paris Cité, Inserm, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, F-75018, Paris, France

    12 shared publications
  • Diane Descamps

    Virology Department, Université Paris Cité, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France

    10 shared publications
  • Jade Ghosn

    Université de Paris Cité, Paris, France

    5 shared publications
  • Margot Bucau

    Service d'Anatomocytopathologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris 18

    5 shared publications
  • Anne Couvelard

    Pathology Department, Université Paris Cité, INSERM, IAME, UMR 1149, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France

    3 shared publications
  • Benoit Visseaux

    Université de Paris, IAME, INSERM, Paris, France; Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France

    3 shared publications

Latest Publications

  • Mécanismes moléculaires et marqueurs biologiques dans la pathogénèse des cancers ano-génitaux HPV induits.

    by Valentine Ferré

    Afin de mieux prévenir les cancers ano-génitaux HPV induits, il est important de mieux comprendre les mécanismes moléculaires de leur pathogénèse mais aussi de trouver des marqueurs biologiques permettant de mieux dépister les stades pré-cancéreux de ces lésions. Dans ce travail de thèse, nous avons d'abord mené deux études épidémiologiques ayant pour but de décrire les HPV circulant en 2017 au sein de deux populations à risque : les hommes ayant des relations sexuelles avec les hommes (HSH) et les femmes travailleuses du sexe (TDS) au Togo, un pays présentant une forte incidence des cancers du col de l'utérus et une importante prévalence du VIH. Nous avons mis en évidence une forte prévalence des infections sexuellement transmissibles mais également une distribution inhabituelle des types d'HPV, l'HPV16 n'étant pas le plus fréquemment détecté. Ainsi, l'HPV16 n'était qu'au 4ème rang en termes de fréquence chez les TDS. Pour les HSH, l'HPV35 était le plus fréquemment détecté, corroborant les résultats de deux études précédentes menées chez les HSH en Afrique Sub-saharienne. Nous avons ensuite comparé les séquences d'un même type d'HPV issues des frottis cervicaux et anaux prélevés de façon concomitante chez les TDS. Grâce à du séquençage viral génome entier, nous avons montré que ces séquences étaient identiques, en faveur de l'hypothèse selon laquelle une grande partie des infections anales féminines seraient liées à une auto-inoculation à partir des infections cervicales. L'analyse des séquences virales a également montré que, malgré une fréquence mutationnelle globale similaire, les mutations induites par APOBEC3 n'étaient pas réparties de façon homogène entre les types d'HPV ni entre les différents groupes de risque oncogène. Ainsi, nous avons démontré sur nos données que les HPV bas-risque (HPVbr) présentaient plus fréquemment des mutations APOBEC3 que les HPV haut-risque (HPVhr), ce que nous avons confirmé par l'analyse des séquences issues de Genbank des HPVhr (HPV16 et 18) et HPVbr (HPV6 et 11) les plus fréquents. Nous avons également montré que ces mutations n'étaient pas réparties de façon homogène le long du génome viral avec un nombre plus élevé de mutations dans les gènes L2 et E1. La différence de signature APOBEC3 entre les groupes d'HPV de différent risque oncogène était retrouvée à l'échelle des gènes viraux, avec une absence de mutations dans les gènes E6 et E4 des HPV16 et 18 alors qu'ils étaient fréquemment mutés dans les HPV6 et 11. Ces motifs de mutations APOBEC différents entre les groupes d'HPV pourrait participer à leur différence de pathogénicité. Dans une dernière étude, nous avons évalué la valeur prédictive de marqueurs de méthylation du génome humain pour l'évolution vers le cancer anal. Ces marqueurs sont bien établis pour le cancer du col de l'utérus et des marqueurs d'intérêt pour le cancer anal ont été mis en évidence par des études transversales sur des biopsies tissulaires (ZNF582 et ASCL1). Notre étude prospective, ancillaire de la cohorte française AIN3, a permis de quantifier ces marqueurs sur des frottis anaux, moins invasifs que les biopsies. Nous avons d'abord démontré que ces marqueurs étaient associés avec les marqueurs classiquement réalisés sur frottis anal : cytologie, double marquage p16/Ki-67, détection d'HPV16 et HPVhr. Nous avons ensuite démontré l'association significative entre le niveau de méthylation de ces marqueurs et l'évolution vers le cancer des patients dans le suivi. Et enfin, nous avons proposé des seuils de méthylation, adaptés à la cohorte AIN3, permettant de démontrer qu'avec des seuils adaptés, ces marqueurs pourraient être implémentés dans les algorithmes de dépistage du cancer anal, par exemple pour orienter vers l'anuscopie haute résolution. Ces résultats contribuent donc à améliorer les connaissances épidémiologiques et mécanistiques des infections HPV et à identifier des marqueurs de triage des lésions anales.

  • HPV and associated cancers: Time to act

    by Valentine Marie Ferré, Charlotte Charpentier

  • Cervical cancer screening: what role for methylation tests?

    by Charlotte Charpentier, Julie Brousseau, Aude Jary, Valentine Marie Ferré

    Cervical cancer is caused by persistent infection with high-risk human papillomaviruses (HR-HPV). Current screening programs rely on cytology and HR-HPV molecular detection. However, as most infections are transient, effective triage for HR-HPV positive women is crucial to identify those at high risk of progression to cancer. DNA methylation analysis, an epigenetic modification involved in HPV-induced oncogenesis, is emerging as a promising triage tool. This marker could stratify risk, thereby reducing invasive examinations (colposcopies) and unnecessary overtreatment (conizations), which may impact future pregnancies. Methylation tests, applicable to both cervical smears and self-collected vaginal samples, target viral genes (e.g., L1, L2) or host cell genes (e.g., FAM19A4, CADM1, MAL). While many markers show good performance, their optimal place in screening strategies and the choice of the most relevant test are still under investigation and require further comparative studies.

  • Anal cancer screening: who, how, and why?

    by Valentine Marie Ferré, Vincent Guillet, Laurent Abramowitz, Jade Ghosn, Margot Bucau, Charlotte Charpentier

    Although anal cancer remains rare in the general population, it is becoming more prevalent, particularly in high-income countries such as France, where the incidence rate is among the highest in the world. Over 90 % of anal cancers are caused by high-risk human papillomavirus (HR-HPV), particularly HPV16. Although two-thirds of cases occur in women, certain groups are at a higher risk, including men who have sex with men (MSM) living with HIV, women living with HIV, women with a history of high-grade vulvar lesions and patients who have received a solid organ transplant more than ten years ago. The ANCHOR randomised trial demonstrated for the first time that treating high-grade squamous intraepithelial lesion (HSIL) significantly reduces the risk of progression to anal cancer in people living with HIV, justifying the implementation of targeted screening strategies. Screening is primarily based on anal cytology and HR-HPV detection, with algorithms varying according to national and international recommendations. In France, a novel approach focusing on HPV16 detection aims to enhance specificity and reduce the reliance on high-resolution anoscopy (HRA), which is considered the gold standard but is not widely accessible. Anal self-sampling appears to be a significant factor in facilitating the implementation of screening, with analytical performance comparable to samples taken by clinicians. Despite ongoing debates about the risk-benefit ratio and cost-effectiveness of anal cancer screening, recent data support its value in high-risk populations. Improvements in triage algorithms, particularly through the use of methylation biomarkers, could optimise the referral of patients requiring HRA in the future and enhance the effectiveness of anal cancer screening by reassuring patients at lower risk of developing cancer. This article aims to provide an overview of the knowledge on which the various anal cancer screening recommendations are based, the means available for implementing this screening, and the obstacles to its implementation.

  • A look back at the 17th Scientific Conference of the Association francophone pour l’étude des infections par les papillomavirus et les polyomavirus (Afipp)

    by Valentine Marie Ferré, Hélène Péré, Céline Bressollette-Bodin, Charlotte Charpentier

  • Genetic landscape of non‐ UV ‐induced cutaneous squamous cell carcinomas

    by Carmen Al Youssef, Mansour Alkobtawi, Rémi Safi, Johan Chanal, Pierre Sohier, Stéphanie Leclerc‐Mercier, Ouidad Zehou, Nicolas Ortonne, Philippe Moguelet, Patricia Senet, et al.

    Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and is most often caused by cumulative UV exposure. However, cSCC may also arise independently of UV exposure, on sites of sustained skin damage like chronic ulcers, scars, Recessive Dystrophic Epidermolysis Bullosa (RDEB), and inflammatory skin diseases such as hidradenitis suppurativa (HS). Little is known about non‐UV‐induced skin carcinomas. We aimed to describe the clinical, pathological, and genetic features, of non‐UV‐induced cSCC. We collected clinical and pathologic data corresponding to 31 patients with non‐UV‐induced cSCC, including 5 cSCC on HS, 4 on chronic leg ulcers and 8 on RDEB. DNA was extracted from FFPE samples and analysed using a NGS assay targeting 523 cancer genes. A comparison was performed with published genetic data obtained in non‐UV‐induced and UV‐induced cSCC. We found that the Tumour Mutational Burden (TMB) of non‐UV‐induced cSCC was 6‐times lower than the published TMB of UV‐induced cSCC. The predominant mutational signature was a clock‐wise signature. By comparing the frequency of driver mutations, we found TP53 and NOTCH1 to be significantly less frequently mutated than in UV‐mutated cSCC. Interestingly, KMT2B (a histone methyl transferase) was mutated in 11/31 non‐UV‐induced cSCC and this proportion was significantly higher than in UV‐mutated cSCC. These mutations were high impact loss‐of‐function mutations. We found that knocking down KMT2B expression using siRNA did not affect cell proliferation of SCC‐13 and A‐431 cell lines, however, it significantly increased cell migration in vitro . Taken together, this study provides a comprehensive description of non‐UV‐induced cSCC and identifies that KMT2B is mutated and involved in non‐UV‐induced cSCC carcinogenesis. © 2025 The Pathological Society of Great Britain and Ireland.

  • Open Access

    High prevalence of bacterial STI, anal HPV, cytological abnormalities and anal lesions among MSM in Togo, 2021: a baseline analysis of the ANRS I MIE 12,400/DepIST-H cohort

    by Valentine M. Ferré, Arnold J. Sadio, Fifonsi A. Gbeasor-Komlanvi, Margot Bucau, Mounerou Salou, Béatrice Berçot, Cécile Bébéar, Laurent Abramowitz, Meryem Zaidi, Amivi P. Amenyah-Ehlan, et al.

    Sexually transmitted infections (STI) are a prominent health issue in Africa, especially in key populations such as men who have sex with men (MSM). Here, we present the baseline results of a 2-year longitudinal cohort in Togo. A total of 200 MSM in Lomé, Togo, were included in the ANRS I MIE 12400/DepIST-H cohort, half living with HIV. High-risk HPV (hrHPV) detection was performed on anal smears. Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT) were tested from urine, pharyngeal and anal swabs. Overall, median age was 23 years, hrHPV prevalence was 75.9%, and was significantly higher in HIV-positive MSM (p = 0.008). The most common hrHPV types were HPV16 and HPV35 (18.7% each). Overall, 55.4% of participants had abnormal anal cytology, the most frequent lesions being low-grade squamous intraepithelial lesions, (22.3% of HIV-positive and 15.2% of HIV-negative MSM). The overall prevalence of GC and CT infections was 32.5% and 32.0%, respectively. Clinical anal lesions, mostly condyloma, were detected in 46.0% of participants (n = 86). These findings emphasize the high prevalence of STIs among MSM and confirm the unusual distribution of HPV types in West Africa, with HPV35 being highly prevalent. A national strategy regarding STI screening and HPV vaccination in this key population is needed. NCT04910438 submitted on 2020-01-22.


  • Open Access

    Higher levels of host-cell DNA methylation markers ZNF582 and ASCL1 on anal smears are predictive for progression to anal cancer in patients with previous high-grade lesions

    by Valentine Marie Ferré, Axelle Dupont, Mélanie Draullette, Emy Valette, Gilles Collin, Margot Bucau, Laurent Siproudhis, Ghislain Staumont, Carine Roy, Albertus Theodorus Hesselink, et al.


  • Vaginal self-sampling for human papillomavirus to improve cervical cancer screening in patients with immune-mediated inflammatory diseases

    by Tiphaine Goulenok, Chrystelle François, Valentine Marie Ferré, Arthur Mageau, Karim Sacré, Eric Hulschulze, Jean-François Alexandra, Marie-Paule Chauveheid, Antoine Dossier, Thomas Papo, et al.


  • Open Access

    Viral whole genome sequencing reveals high variations in APOBEC3 editing between HPV risk categories

    by Valentine Marie Ferré, Romain Coppée, Fifonsi A. Gbeasor‐Komlanvi, Sophie Vacher, Antoine Bridier‐Nahmias, Margot Bucau, Mounerou Salou, Sonia Lameiras, Anne Couvelard, Anoumou Claver Dagnra, et al.

    High‐risk human papillomavirus (HPV) infections are responsible for cervical cancer. However, little is known about the differences between HPV types and risk categories regarding their genetic diversity and particularly APOBEC3‐induced mutations – which contribute to the innate immune response to HPV. Using a capture‐based next‐generation sequencing, 156 HPV whole genome sequences covering 43 HPV types were generated from paired cervical and anal swabs of 30 Togolese female sex workers (FSWs) sampled in 2017. Genetic diversity and APOBEC3‐induced mutations were assessed at the viral whole genome and gene levels. Thirty‐four pairwise sequence comparisons covering 24 HPV types in cervical and anal swabs revealed identical infections in the two anatomical sites. Differences in genetic diversity among HPV types was observed between patients. The E6 gene was significantly less conserved in low‐risk HPVs (lrHPVs) compared to high‐risk HPVs (hrHPVs) ( p = 0.009). APOBEC3‐induced mutations were found to be more common in lrHPVs than in hrHPVs ( p = 0.005), supported by our data and by using large HPV sequence collections from the GenBank database. Focusing on the most common lrHPVs 6 and 11 and hrHPVs 16 and 18, APOBEC3‐induced mutations were predominantly found in the E4 and E6 genes in lrHPVs, but were almost absent in these genes in hrHPVs. The variable APOBEC3 mutational signatures could contribute to the different oncogenic potentials between HPVs. Further studies are needed to conclusively determine whether APOBEC3 editing levels are associated to the carcinogenic potential of HPVs at the type and sublineage scales.